Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ImmuPharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Lupus Erythematosus, Systemic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IP-006 | P3 |
Completed |
Lupus Erythematosus, Systemic |
2019-02-05 |
72% |
| 2017-004060-35 | P3 |
Completed |
Lupus Erythematosus, Systemic |
2019-02-05 |
|
| A study to evaluate the effectiveness and safety of the study drug for patients with SLE. | P3 |
Completed |
Lupus Erythematosus, Systemic |
2018-01-24 |
|
| LUPUZOR | P3 |
Completed |
Lupus Erythematosus, Systemic |
2018-01-01 |